137 related articles for article (PubMed ID: 20006709)
1. Expression of soluble and functional human neonatal Fc receptor in Pichia pastoris.
Lee CH; Choi DK; Choi HJ; Song MY; Kim YS
Protein Expr Purif; 2010 May; 71(1):42-8. PubMed ID: 20006709
[TBL] [Abstract][Full Text] [Related]
2. A strategy for bacterial production of a soluble functional human neonatal Fc receptor.
Andersen JT; Justesen S; Berntzen G; Michaelsen TE; Lauvrak V; Fleckenstein B; Buus S; Sandlie I
J Immunol Methods; 2008 Feb; 331(1-2):39-49. PubMed ID: 18155020
[TBL] [Abstract][Full Text] [Related]
3. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies.
Magistrelli G; Malinge P; Anceriz N; Desmurs M; Venet S; Calloud S; Daubeuf B; Kosco-Vilbois M; Fischer N
J Immunol Methods; 2012 Jan; 375(1-2):20-9. PubMed ID: 21939661
[TBL] [Abstract][Full Text] [Related]
4. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
5. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
6. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
[TBL] [Abstract][Full Text] [Related]
7. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
9. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
10. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
[TBL] [Abstract][Full Text] [Related]
11. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
[TBL] [Abstract][Full Text] [Related]
12. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor.
Feng Y; Gong R; Dimitrov DS
Protein Expr Purif; 2011 Sep; 79(1):66-71. PubMed ID: 21453773
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
[TBL] [Abstract][Full Text] [Related]
14. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
15. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
16. Reduced elimination of IgG antibodies by engineering the variable region.
Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
[TBL] [Abstract][Full Text] [Related]
17. FcRn: the neonatal Fc receptor comes of age.
Roopenian DC; Akilesh S
Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
[TBL] [Abstract][Full Text] [Related]
19. Quantitative methods for developing Fc mutants with extended half-lives.
Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
[TBL] [Abstract][Full Text] [Related]
20. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.
Andersen JT; Daba MB; Berntzen G; Michaelsen TE; Sandlie I
J Biol Chem; 2010 Feb; 285(7):4826-36. PubMed ID: 20018855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]